An Open-Label, Multi-Center Clinical Trial of Eculizumab in Adult Patients with Atypical Hemolytic-Uremic Syndrome

Phase 2

Withdrawn

• Conditions: atypical hemolytic-uremic syndrome; 10018911; 10027665; 10029149

• Registration Number: NL-OMON34263
• Lead Sponsor: Alexion Pharmaceuticals

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 8

Inclusion Criteria

1. Patient must be willing and able to give written informed consent.
2. Patient*s age * 18 years.
3. Patients exhibit thrombocytopenia, hemolysis and elevated Serum Creatinine

Exclusion Criteria

1. Chronic dialysis
2. Prior eculizumab use or hypersensitivity to eculizumab

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The proportion of patients with aHUS with complete TMA response.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Safety and efficacy.</p><br>